284 related articles for article (PubMed ID: 21199698)
1. The development of vaccine viruses against pandemic A(H1N1) influenza.
Robertson JS; Nicolson C; Harvey R; Johnson R; Major D; Guilfoyle K; Roseby S; Newman R; Collin R; Wallis C; Engelhardt OG; Wood JM; Le J; Manojkumar R; Pokorny BA; Silverman J; Devis R; Bucher D; Verity E; Agius C; Camuglia S; Ong C; Rockman S; Curtis A; Schoofs P; Zoueva O; Xie H; Li X; Lin Z; Ye Z; Chen LM; O'Neill E; Balish A; Lipatov AS; Guo Z; Isakova I; Davis CT; Rivailler P; Gustin KM; Belser JA; Maines TR; Tumpey TM; Xu X; Katz JM; Klimov A; Cox NJ; Donis RO
Vaccine; 2011 Feb; 29(9):1836-43. PubMed ID: 21199698
[TBL] [Abstract][Full Text] [Related]
2. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.
Abelin A; Colegate T; Gardner S; Hehme N; Palache A
Vaccine; 2011 Feb; 29(6):1135-8. PubMed ID: 21115061
[TBL] [Abstract][Full Text] [Related]
3. Pandemic influenza A (H1N1) 2009 vaccine: an update.
Goel MK; Goel M; Khanna P; Mittal K
Indian J Med Microbiol; 2011; 29(1):13-8. PubMed ID: 21304188
[TBL] [Abstract][Full Text] [Related]
4. Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine.
Chao DY; Cheng KF; Hsieh YH; Li TC; Wu TN; Chen CY; Tsai CA; Chen JH; Chiu HT; Lu JJ; Su MC; Liao YH;
Vaccine; 2011 Jan; 29(4):617-23. PubMed ID: 21095255
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial.
Dikow R; Eckerle I; Ksoll-Rudek D; Hampel H; Schwenger V; Zeier M; Schnitzler P; Sommerer C
Am J Kidney Dis; 2011 May; 57(5):716-23. PubMed ID: 21349617
[TBL] [Abstract][Full Text] [Related]
6. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
[TBL] [Abstract][Full Text] [Related]
7. A note on the use of influenza vaccination strategies when supply is limited.
Lee S; Morales R; Castillo-Chavez C
Math Biosci Eng; 2011 Jan; 8(1):171-82. PubMed ID: 21361406
[TBL] [Abstract][Full Text] [Related]
8. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
[TBL] [Abstract][Full Text] [Related]
9. Pandemic 2009-2010 influenza vaccine: six lessons learned and the way forward (Allegro not Adagio).
Poland GA
Vaccine; 2011 Jan; 29(4):613-4. PubMed ID: 21193121
[No Abstract] [Full Text] [Related]
10. Influenza vaccines: the good, the bad, and the eggs.
Schultz-Cherry S; Jones JC
Adv Virus Res; 2010; 77():63-84. PubMed ID: 20951870
[TBL] [Abstract][Full Text] [Related]
11. Vaccination against influenza: role and limitations in pandemic intervention plans.
Rebmann T; Zelicoff A
Expert Rev Vaccines; 2012 Aug; 11(8):1009-19. PubMed ID: 23002981
[TBL] [Abstract][Full Text] [Related]
12. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D
Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428
[TBL] [Abstract][Full Text] [Related]
13. Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza.
Prosper O; Saucedo O; Thompson D; Torres-Garcia G; Wang X; Castillo-Chavez C
Math Biosci Eng; 2011 Jan; 8(1):141-70. PubMed ID: 21361405
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
[TBL] [Abstract][Full Text] [Related]
15. Exploring synergies between academia and vaccine manufacturers: a pilot study on how to rapidly produce vaccines to combat emerging pathogens.
Strecker T; Uhlendorff J; Diederich S; Lenz-Bauer C; Trusheim H; Roth B; Kolesnikova L; Aepinus C; Dornow R; Gerlach J; Matrosovich M; Valley U; Eickmann M; Becker S
Clin Chem Lab Med; 2012 May; 50(7):1275-9. PubMed ID: 22850059
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
17. Animal models for the preclinical evaluation of candidate influenza vaccines.
Bodewes R; Rimmelzwaan GF; Osterhaus AD
Expert Rev Vaccines; 2010 Jan; 9(1):59-72. PubMed ID: 20021306
[TBL] [Abstract][Full Text] [Related]
18. Acceptance of a vaccine against pandemic influenza A (H1N1) virus amongst healthcare workers in Beijing, China.
Seale H; Kaur R; Wang Q; Yang P; Zhang Y; Wang X; Li X; Zhang H; Zhang Z; MacIntyre CR
Vaccine; 2011 Feb; 29(8):1605-10. PubMed ID: 21211593
[TBL] [Abstract][Full Text] [Related]
19. DNA-based influenza vaccines: evaluating their potential to provide universal protection.
Choo AY; Broderick KE; Kim JJ; Sardesai NY
IDrugs; 2010 Oct; 13(10):707-12. PubMed ID: 20878593
[TBL] [Abstract][Full Text] [Related]
20. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus.
Pushko P; Kort T; Nathan M; Pearce MB; Smith G; Tumpey TM
Vaccine; 2010 Jul; 28(30):4771-6. PubMed ID: 20470801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
